(CRDF) – Management Comments
-
Cardiff Oncology (CRDF) Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
-
Cardiff Oncology (CRDF) Reports First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan & 5-FU in Pancreatic Cancer
-
-
-
-
-
-
Back to CRDF Stock Lookup